Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.